However, the study does not provide definitive evidence linking genetic proxies for primary antihypertensive treatments, such as ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs), or other medications, with the decreasing risk of HT. The gene discussed is ACE; the disease is hematocrit.